LENZ Therapeutics, Inc.
LENZHealthcare|Biotechnology|US
$3.50
+0.49 (+16.28%)
DCF Value
$2.33
Tangible Book / Share
$6.11
Cash / Share
$6.28
Clinical Trials (11)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07464457 Effects of Neoadjuvant Prehabilitation on Post-Interventional Physical and Psychological Outcomes in Oncology Patients With Solid Tumors | Breast Cancer, Solid Tumor | N/A | Recruiting | 125 | Open-label | — |
| NCT06045299 Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia | Presbyopia, Near Vision | P3 | Completed | 300 | RCT, Double-blind | Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Placebo (Vehicle) ophthalmic solution |
| NCT05656027 Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia | Presbyopia, Refractive Error | P3 | Completed | 469 | RCT, Double-blind | Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Brimonidine |
| NCT05728944 Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia | Presbyopia, Near Vision | P3 | Completed | 229 | RCT, Double-blind | Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Vehicle |
| NCT05753189 Phase 3 Safety Study of LNZ100 and LNZ101 for the Treatment of Presbyopia Subjects | Presbyopia, Near Vision | P3 | Completed | 362 | RCT, Double-blind | Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Vehicle |
| NCT03201562 A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia | Presbyopia | P2 | Completed | 58 | RCT, Double-blind | Aceclidine+tropicamide combination, Aceclidine, Vehicle |
| NCT02554396 Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia | Presbyopia | P2 | Completed | 20 | RCT, Double-blind | PRX-100, Placebo |
| NCT05294328 Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia | Presbyopia, Refractive Errors | P2 | Completed | 68 | RCT, Double-blind | Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Vehicle Proprietary Ophthalmic Solution |
| NCT05431543 Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia | Presbyopia, Refractive Errors | P2 | Completed | 59 | RCT, Double-blind | Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Vehicle proprietary ophthalmic solution |
| NCT06270030 Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia | Presbyopia | P1 | Completed | 21 | RCT, Single-blind | LNZ101 (Aceclidine /Brimonidine) ophthalmic solution, LNZ100 (Aceclidine) ophthalmic solution, Placebo (Vehicle) ophthalmic solution |
| NCT05936489 Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia | Eye Diseases, Presbyopia | P1 | Completed | 30 | RCT, Open-label | Aceclidine + Brimonidine, Aceclidine |